Why this Smallcap Biotech Will Soar Soon!

Dr. Thomas Carr

March 24, 2017 10:38am

Cempra, Inc. (NASDAQ: CEMP) is an American, clinical-stage biotechnology company focused on developing anti-infectives for the acute care and communal diseases sectors. Its 2 lead products in the pipeline are Solithromycin, which is in Phase III trials for the treatment of bacterial pneumonia in adults and children, and Fusidic Acid, also in Phase III for the treatement of bacterial skin infections. Obviously these are huge markets, and Cempra's products have an edge over competitors due to their wide range of distributive options. Cempra also has a third drug, Taksta, which is set to read out Phase III results sometime this quarter...so any day now. Shares of CEMP were hit hard late last year on an FDA rejection, but the concerns were more about safety issues than about effectiveness. The drug involved, Solithromycin, also has other applications at a lower dosage which may help resolve this issue. And European regulators are more optimistic on the drug than their US counterparts since curing the otherwise fatal disease, in their estimates, is a better payoff than the risk of liver disease associated with the drug.

On 2/27/17, ROTH Capital gave Cempra an upgrade, moving its assessment from "Neutral" to "Buy." This followed a successful Phase III trial for its skin drug. Prior to that, in late December, Margan Stanley move shares from "Underweight" to "Equal-Weight". Our research shows that for every upgrade a company receives from a major analyst, shares rise 500 basis points more than the S&P 500 over the next quarter. This means we should expect at least a 10% alpha move from CEMP over the next 3 months. Cempra has also recently retained Morgan Stanley as a business strategist. The company has $215M in cash which is greater ...

Read More
Comments

The GoPro Bounce: Can it Last?

After the close of trading on Wednesday, March 15, GoPro (Nasdaq: GPRO) surprised the market when it released its Q1 earnings results. The sport-camera maker hit its revenue target and earnings were on par with expectations, but really got the ...

Read More
Comments

Intel the New Must-Own Stock for the Next Decade

Intel The New Must-Own Stock For The Next Decade

March 15, 2017 3:38pm

Intel Corporation (Nasdaq: INTC) has long been one of the top two or three must-own stocks among blue chip tech companies. It has been part of ...

Read More
Comments

$ORIG Hammered: Is This a Buying Opportunity?

The stock price of Ocean Rig UDW, LLC (Nasdaq: ORIG), a deep-sea drilling outfit, has been on a roller coaster ride of late. The stock has really struggled, as have the stocks of all the companies in the space...largely ...

Read More
Comments

Why This Smallcap Heavy Machinery Stock is a Strong Buy

Manitex International (MNTX) makes lifting and loading machinery (think small cranes, forklifts, bulldozers, etc.) and sells them throughout the world through a number of well known brands. All work is done in house. The company was found in Bridgeview, Illinois ...

Read More
Comments

It's Time to Buy Biotech

Yes there is political risk in this very volatile and speculative, "risk-on" market space...but that is what makes this trade so intriguing. One tweet from newly elected President Trump last week caused a 12 point drop in the $IBB ...

Read More
Comments

How to Make Money Going LONG in a BEAR MARKET

Yes, you can make money BUYING stocks in a BEAR Market. But you must understand the fundamental and technical dynamics that propel stocks higher even as most stocks are falling. In this short educational video, Dr. Stoxx (aka Dr. Thomas ...

Read More
Comments

Buy Cobalt Energy (CIE)

Cobalt International Energy, Inc. operates as an oil and gas exploration and production company primarily in the deepwater U.S. Gulf of Mexico. The company holds interests in the North Platte, Shenandoah, Anchor, and Heidelberg fields located in the U ...

Read More
Comments

How to Make $10B in Stocks the Templeton Way

How To Make $10B In Stocks Trading The Templeton Way

Dr. Thomas Carr

January 10, 2017

Sir John Templeton (1912 to 2008) was American born but lived in England where he established himself as a successful investor and pioneer in ...

Read More
Comments

Why Bonanza Creek Energy (BCEI) is Rallying Today

Bonanza Creek Energy Inc. engages in the development and production of onshore oil and natural gas in the United States. The company's oil and liquids weighted assets are located primarily in the Wattenberg Field in Colorado; and the Dorcheat ...

Read More
Comments

Why Capstone Turbine (CPST) is a Buy

Capstone Turbine Corporation has been identified by our DrStoxx.com team as a strong buy for 2017. Capstone develops, manufactures, markets, and services microturbine technology solutions for use in power generation applications worldwide. The company's microturbines are also used ...

Read More
Comments

Why the Market is Headed Lower from Here

Why The Market Is Headed Lower Still

Dr. Thomas Carr

| November 1, 2016 5:56pm

In this short video, Dr. Carr offers his analysis of the S&P 500 following Tuesday's sharp selloff. He has detected a rare but very ...

Read More
Comments